Du, Juan
Zhao, Zhihao
Zhao, Hetong
Liu, Dong
Liu, Hui
Chen, Jun
Cheng, Binbin
Zhai, Xiaofeng
Yin, Zifei
Zhang, Yani
Ling, Changquan
Funding for this research was provided by:
National Natural Science Foundation of China (81473484)
Nature Science Foundation of Shanghai
Article History
Received: 15 July 2019
Revised: 19 November 2019
Accepted: 25 November 2019
First Online: 10 December 2019
Conflict of interest
: The authors declare that they have no conflict of interest.
: The study was approved by Changhai Hosipital Ethic Committee in Changhai Hospital, Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University and Zhongshan Hospital, Fudan University. The study had been registered with Chinese Clinical Trials Registry, number ChiCTR-TRC-07000033 and was performed in accordance with the Declaration of Helsinki. Animal experiments were approved by Animal Ethics Committee of Zhongshan Hospital. Only male mice were used since the study aimed to identify mechanisms and a prognostic biomarker of HCC recurrence, which is high in male.